Live
- Hailstorm-hit Vistara flight returns to Bhubaneswar airport
- PM Modi-led govt saved people during pandemic: Union Minister Anurag Thakur
- Heat wave grips Telangana, mercury crosses 46 degrees Celsius in few places
- New India believes in giving a dose, not dossiers, to terror masterminds: PM Modi
- Nagarkurnool MLA Kuchukulla Rajesh Reddy should send Malluravi to Parliament for the third time
- Awareness conference on Mayday under the auspices of Legal Service Authority
- Adani Power logs 37 per cent revenue growth in FY24, consolidated PBT more than doubled
- Rohit said 'just show us what you can do', recalls Shivam Dube post T20 WC selection
- Resignations of Lovely, Naseeb and Basoya indicate Congress high command's disconnect with ground reality
- Hamas standing in way of ceasefire, Blinken says during meeting with Israeli PM Netanyahu
Zydus gets USFDA nod for generic anti-pregnancy medication
Zydus Lifesciences on Friday said it has received final approval from the US health regulator to market a generic medication to prevent pregnancy.
Zydus Lifesciences on Friday said it has received final approval from the US health regulator to market a generic medication to prevent pregnancy.
The company has received final approval from the US Food and Drug Administration (USFDA) for Norelgestromin and Ethinyl Estradiol Transdermal System (150 mcg/35 mcg per day), the drug firm said in a statement.
Norelgestromin and Ethinyl Estradiol Transdermal System contains combination hormone medication and is used to prevent pregnancy.
The transdermal patch will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, Zydus Lifesciences said.
As per IQVIA MAT data, Norelgestromin and Ethinyl Estradiol Transdermal System (150 mcg/35 mcg) had annual sales of USD 330 million in the US market. Shares of the company settled 0.93 per cent up at Rs 645.65 apiece on the BSE.
